Strumento inattivo

Altre lingue MAXO CAP

Azioni

JMAC

US57778T1060

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Maxpro Capital Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23
Apollomics Announces Completion of Business Combination and Listing on Nasdaq	30/03/23
Maxpro Capital Acquisition Corp.(NasdaqGM:JMAC) dropped from NASDAQ Composite Index	29/03/23
Apollomics, Inc. completed the acquisition of Maxpro Capital Acquisition Corp. from MP One Investment LLC and others in a reverse merger.	29/03/23
MAXPRO CAPITAL ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	21/03/23
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	10/02/23
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	13/01/23
Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination	13/01/23
Maxpro Capital Acquisition Extends Deadline to Complete Business Combination	11/01/23
MAXPRO CAPITAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)	10/01/23
Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination	10/01/23
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	29/11/22
Maxpro Capital Acquisition Corp. announced that it has received $0.5 million in funding from MP One Investment LLC	23/11/22
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations	16/11/22
Apollomics Gets Orphan Drug Designation for Vebreltinib to Treat Lung Cancer	15/11/22
MAXPRO CAPITAL ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	02/11/22
Maxpro Capital Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	02/11/22
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	14/10/22
Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination	14/10/22
MAXPRO CAPITAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)	07/10/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue MAXO CAP

Azioni

JMAC

US57778T1060

Altre lingue

Filtri